Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

The New York Stock Exchange is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update?for market insights before trading begins.  Kristen ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.

HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a ...

Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) ...

Health care providers at the John B. Amos Cancer Center in Columbus, Georgia are among the first in the state to administer a new therapy for cancer treatment. Phenix City, Alabama resident Susan ...

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.